72 related articles for article (PubMed ID: 10592904)
1. Two possible pathways for acquisition of mutations related to nelfinavir resistance.
Sugiura W; Oishi T; Okano A; Matsuda M; Abumi H; Yamada K; Koike M; Taki M; Ishikawa M; Miura T; Fukutake K; Gouchi K; Ajisawa A; Iwamoto A; Hanabusa H; Mimaya J; Takamatsu J; Takata N; Kakishita E; Higasa S; Kashiwagi S; Shirahata A; Nagai Y
Jpn J Infect Dis; 1999 Aug; 52(4):175-6. PubMed ID: 10592904
[No Abstract] [Full Text] [Related]
2. Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments.
Garriga C; Pérez-Elías MJ; Delgado R; Ruiz L; Nájera R; Pumarola T; Alonso-Socas Mdel M; García-Bujalance S; Menéndez-Arias L;
J Med Virol; 2007 Nov; 79(11):1617-28. PubMed ID: 17854027
[TBL] [Abstract][Full Text] [Related]
3. [Diabetes and hyperglycemia in patients under treatment for HIV infection with the protease inhibitors indavir, ritonavir, saquinavir as well as nelfinavir (in development, but not yet released].
Pharm Unserer Zeit; 1997 Dec; 26(6):317. PubMed ID: 9513575
[No Abstract] [Full Text] [Related]
4. The choice of HIV protease inhibitor: indinavir is currently the best option.
Prescrire Int; 1999 Apr; 8(40):55-60. PubMed ID: 10848067
[TBL] [Abstract][Full Text] [Related]
5. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine.
Kempf DJ; King MS; Bernstein B; Cernohous P; Bauer E; Moseley J; Gu K; Hsu A; Brun S; Sun E
J Infect Dis; 2004 Jan; 189(1):51-60. PubMed ID: 14702153
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of the HIV-1 protease mutation I47A in clinical practice and association with lopinavir resistance.
de Mendoza C; Valer L; Bacheler L; Pattery T; Corral A; Soriano V
AIDS; 2006 Apr; 20(7):1071-4. PubMed ID: 16603864
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic drug monitoring of saquinavir in patients during protease inhibitor therapy with saquinavir alone or in combination with ritonavir or nelfinavir.
Langmann P; Zilly M; Weissbrich B; Schlör C; Väth T; Richter E; Klinker H
Eur J Med Res; 2000 Feb; 5(2):59-62. PubMed ID: 10720564
[TBL] [Abstract][Full Text] [Related]
8. Nelfinavir is number 4 -- but should it bat cleanup, or lead off?
Mascolini M
J Int Assoc Physicians AIDS Care; 1997 Jun; 3(6):17-21. PubMed ID: 11364427
[TBL] [Abstract][Full Text] [Related]
9. Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy.
Condra JH; Petropoulos CJ; Ziermann R; Schleif WA; Shivaprakash M; Emini EA
J Infect Dis; 2000 Sep; 182(3):758-65. PubMed ID: 10950769
[TBL] [Abstract][Full Text] [Related]
10. [Resistance to protease inhibitors].
Clotet B; Martínez-Picado J; Arrizabalaga J; Ruiz L
Enferm Infecc Microbiol Clin; 2001 Feb; 19(Monografico):34-41. PubMed ID: 11428058
[No Abstract] [Full Text] [Related]
11. What they say about protease inhibitors.
Posit Aware; 1999; 10(1):38-43. PubMed ID: 11366522
[TBL] [Abstract][Full Text] [Related]
12. Nelfinavir (Viracept).
Res Initiat Treat Action; 2000 Mar; 6(1):30-1. PubMed ID: 11708185
[No Abstract] [Full Text] [Related]
13. Hyperlipidemia associated with the use of protease inhibitors.
Smith JH; Martin GJ; Decker CF
Clin Infect Dis; 2000 Jul; 31(1):207-8. PubMed ID: 10913432
[No Abstract] [Full Text] [Related]
14. Protease inhibitors: resistance, resistance, resistance.
Gilden D; Falkenberg J; Torres G
GMHC Treat Issues; 1997 Feb; 11(2):5-10. PubMed ID: 11364108
[TBL] [Abstract][Full Text] [Related]
15. What they say about: protease inhibitors.
Posit Aware; 2000; 11(1):48-54. PubMed ID: 11366351
[TBL] [Abstract][Full Text] [Related]
16. Clinical validation of saquinavir/ritonavir genotypic resistance score in protease-inhibitor-experienced patients.
Marcelin AG; Flandre P; de Mendoza C; Roquebert B; Peytavin G; Valer L; Wirden M; Abbas S; Katlama C; Soriano V; Calvez V
Antivir Ther; 2007; 12(2):247-52. PubMed ID: 17503666
[TBL] [Abstract][Full Text] [Related]
17. Absence of resistance mutations in antiretroviral-naive patients treated with ritonavir-boosted saquinavir.
Ananworanich J; Hirschel B; Sirivichayakul S; Ubolyam S; Jupimai T; Prasithsirikul W; Chetchotisakd P; Kiertiburanakul S; Munsakul W; Raksakulkarn P; Tansuphasawadikul S; Schutz M; Snowden W; Ruxrungtham K;
Antivir Ther; 2006; 11(5):631-5. PubMed ID: 16964832
[TBL] [Abstract][Full Text] [Related]
18. Kaletra versus nelfinavir.
TreatmentUpdate; 2001; 12(12):8-10. PubMed ID: 11570097
[No Abstract] [Full Text] [Related]
19. The effects of antiretroviral protease inhibitors on serum lipid levels in HIV-infected patients.
Chang ES; Tetreault DD; Liu YT; Beall GN
J Am Diet Assoc; 2001 Jun; 101(6):687-9. PubMed ID: 11424549
[No Abstract] [Full Text] [Related]
20. Discordant genotypic interpretation and phenotypic role of protease mutations in HIV-1 subtypes B and G.
Santos AF; Abecasis AB; Vandamme AM; Camacho RJ; Soares MA
J Antimicrob Chemother; 2009 Mar; 63(3):593-9. PubMed ID: 19136678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
